JP5099956B2 - New anti-inflammatory analgesic cataplasm - Google Patents

New anti-inflammatory analgesic cataplasm Download PDF

Info

Publication number
JP5099956B2
JP5099956B2 JP2003426144A JP2003426144A JP5099956B2 JP 5099956 B2 JP5099956 B2 JP 5099956B2 JP 2003426144 A JP2003426144 A JP 2003426144A JP 2003426144 A JP2003426144 A JP 2003426144A JP 5099956 B2 JP5099956 B2 JP 5099956B2
Authority
JP
Japan
Prior art keywords
felbinac
adhesive base
cataplasm
disperse
menthol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003426144A
Other languages
Japanese (ja)
Other versions
JP2005179312A (en
Inventor
智行 日溪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Priority to JP2003426144A priority Critical patent/JP5099956B2/en
Publication of JP2005179312A publication Critical patent/JP2005179312A/en
Application granted granted Critical
Publication of JP5099956B2 publication Critical patent/JP5099956B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

本発明は、消炎鎮痛用パップ剤に関する。
詳しくは、本発明は、フェルビナク(4−ビフェニル酢酸)及び/又はその薬学的に許容し得る塩を有効成分として含有する消炎鎮痛用分散型パップ剤に関する。
The present invention relates to an anti-inflammatory analgesic poultice.
In detail, this invention relates to the dispersal type | formula poultice for anti-inflammatory analgesia which contains felbinac (4-biphenylacetic acid) and / or its pharmaceutically acceptable salt as an active ingredient.

パップ剤は、粘着基剤中に水を含有するため冷却効果に優れ、古くから捻挫や筋肉痛に使用されており、更に炎症そのものを抑制するためケトプロフェンやインドメタシンなどの抗炎症剤を基剤中に溶解させたものが知られている。
これら抗炎症剤のうち、分子中にカルボン酸基を有するものはl−メントールとl−メントールエステル体を形成することが知られており、このエステル化防止対策として脂肪酸金属塩を用いる方法が特許文献1に開示されているが、フェルビナクのパップ剤においては、これでも十分安定であるとは言えず、更なる主薬の安定化が望まれていた。
一方、抗炎症剤として優れた効果を発揮し得るフェルビナクにおいては、水、アルコール等に非常に難溶性であるため、貼付剤等の製剤化が困難であった。
その問題点を解決するため特許文献2ではパップ剤の粘着基剤中にクロタミトンを吸収助剤として含有させてフェルビナクのパップ剤としての製剤化が試みられおり、また、特許文献3には、フェルビナク(1%)、イソステアリン酸ポリエチレングリコール(3%)及び5−メチル−2−ピロリドン(5%)から成るクリーム剤(溶解型製剤)が開示されているが、何れも製剤安定性が十分とはいえず、好ましいものではなかった。
Pap agents contain water in the adhesive base and have an excellent cooling effect. They have long been used for sprains and myalgia. In addition, anti-inflammatory agents such as ketoprofen and indomethacin are used as a base to suppress inflammation itself. What is dissolved in is known.
Among these anti-inflammatory agents, those having a carboxylic acid group in the molecule are known to form l-menthol and l-menthol ester, and a method using a fatty acid metal salt as a countermeasure against this esterification is patented. Although it is disclosed in Document 1, it cannot be said that Ferbinac's poultice is still sufficiently stable, and further stabilization of the main drug has been desired.
On the other hand, felbinac, which can exert an excellent effect as an anti-inflammatory agent, is very poorly soluble in water, alcohol and the like, and thus it has been difficult to formulate patches and the like.
In order to solve the problem, Patent Document 2 attempts to formulate felbinac as a poultice by adding crotamiton as an absorption aid in the adhesive base of the poultice, and Patent Document 3 discloses felbinac. (1%), polyethylene glycol isostearate (3%) and 5-methyl-2-pyrrolidone (5%) are disclosed as creams (dissolvable preparations), all of which have sufficient preparation stability No, it was not preferable.

特許第3238409号明細書Japanese Patent No. 3238409 特開平3−193728号公報Japanese Patent Laid-Open No. 3-193728 特開平11−199521号公報JP-A-11-199521

本発明は、上記した如き現状に鑑みなされたもので、製剤安定性が極めて良効で、且つ実用性の高いフェルビナク含有パップ剤を提供することを目的とする。   The present invention has been made in view of the above-described situation, and an object of the present invention is to provide a felbinac-containing cataplasm containing an extremely effective formulation and having high practicality.

上記目的を達成するため、本発明は、以下の構成からなる。
「フェルビナク及び/又はその薬学的に許容し得る塩と、l−メントール、及び親水性の高い界面活性剤を粘着基剤中に含んでなることを特徴とする、分散型フェルビナク含有パップ剤。」
In order to achieve the above object, the present invention has the following configuration.
“Dispersed felbinac-containing cataplasm containing a felbinac and / or a pharmaceutically acceptable salt thereof, l-menthol, and a highly hydrophilic surfactant in an adhesive base.”

即ち、本発明者らは、フェルビナクを溶解させずに、粘着基剤中に分散させることにより、l−メントールを粘着基剤中に含有させてもl−メントールエステル体を生成せず、フェルビナクが粘着基剤中に安定に保てるのではないかと考え、鋭意研究を重ねた結果、フェルビナクとl−メントールが共存する粘着基剤中に、更に、親水性の高い界面活性剤を共存させることによりフェルビナクが粘着基剤中に安定に保持され、結果的に製剤安定性が良好で、且つ実用性の高いパップ剤が得られることを見出し、本発明を完成するに到った。
なお、本発明では、単にフェルビナクを分散するだけではなく、均一に分散させる事が特徴の一つとする。
That is, the present inventors do not dissolve felbinac but disperse it in the adhesive base, so that l-menthol ester is not produced even if l-menthol is contained in the adhesive base. As a result of intensive research, we thought that it could be kept stable in the adhesive base. As a result, fervinac was further obtained by coexisting a highly hydrophilic surfactant in the adhesive base where felbinac and l-menthol coexisted. Was stably held in the adhesive base, and as a result, a cataplasm having good formulation stability and high practicality was obtained, and the present invention was completed.
In the present invention, it is one of the features that the ferbinac is not only dispersed but also uniformly dispersed.

本発明は、製剤安定性が極めて良効で、且つ実用性の高いフェルビナク含有パップ剤を提供するものである点に顕著な効果を奏する。   The present invention has a remarkable effect in that it provides a felbinac-containing cataplasm having an extremely good formulation stability and high practicality.

本発明のパップ剤は、フェルビナク及び/又はその薬学的に許容し得る塩と、l−メントール、及び親水性の高い界面活性剤を粘着基剤中に含んでなることを特徴とするものであるが、本発明で用いられる親水性の高い界面活性剤の好ましいものとしては、例えば、親水性の高い非イオン界面活性剤が挙げられる。本発明に係る親水性の高い非イオン界面活性剤としては、例えばHLB値が10以上の非イオン界面活性剤が挙げられる。このような親水性の高い非イオン界面活性剤の具体例としては、例えば、ポリエチレングリコール脂肪酸エステル(例えば、モノステアリン酸ポリエチレングリコール(10)等)やポリオキシエチレンソルビタン脂肪酸エステル(例えば、モノオレイン酸ポリオキシエチレン(20)ソルビタン等)等が挙げられる。   The cataplasm of the present invention comprises felbinac and / or a pharmaceutically acceptable salt thereof, l-menthol, and a highly hydrophilic surfactant in an adhesive base. However, as a preferable thing of the highly hydrophilic surfactant used by this invention, a highly hydrophilic nonionic surfactant is mentioned, for example. Examples of the highly hydrophilic nonionic surfactant according to the present invention include nonionic surfactants having an HLB value of 10 or more. Specific examples of such highly hydrophilic nonionic surfactants include, for example, polyethylene glycol fatty acid esters (eg, polyethylene glycol monostearate (10)) and polyoxyethylene sorbitan fatty acid esters (eg, monooleic acid). Polyoxyethylene (20) sorbitan, etc.).

本発明のパップ剤において、分散性をより高める目的で、粘着基剤中に更にポリエチレングリコール、ポリプロピレングリコール等の分散溶媒を含有させることも好ましい態様の一つである。   In the cataplasm of the present invention, for the purpose of further improving dispersibility, it is also one of preferred embodiments that a dispersion solvent such as polyethylene glycol and polypropylene glycol is further contained in the adhesive base.

本発明のパップ剤における上記以外の成分としては、通常パップ剤で用いられる一般的な成分、即ち、増粘剤、湿潤剤(保湿剤)、充填剤(賦形剤)、吸収促進剤、防腐剤、抗酸化剤、この種製剤における一般的な安定化剤等々が挙げられる。
増粘剤としては、例えば、ポリアクリル酸ナトリウム、ポリアクリル酸、ポリビニルアルコール、ポリビニルピロリドン等の合成水溶性高分子、カルボキシメチルセルロースNa、メチルセルロール、ヒドロキシメチルセルロース等の天然高分子誘導体、デンプン、ゼラチン等の天然物等が挙げられる。
湿潤剤(保湿剤)としては、例えば、グリセリン、プロピレングリコール、1,3−ブチレングリコール、ソルビトール等の多価アルコール挙げられる。
充填剤(賦形剤)としては、例えば、カオリン、亜鉛華、酸化チタン、タルク、ベントナイト、含水ケイ酸アルミニウム、メタケイ酸アルミン酸マグネシウム等の無機物が挙げられる。なお、酸化チタンの場合には、充填剤(賦形剤)として以外にも、粉体の分散補助の目的でも使用し得るので、充填剤(賦形剤)として他の無機物を使用した場合でも、必要に応じて更に酸化チタンを含有させることも好ましい態様の一つである。
吸収促進剤としては、例えば、エタノール、プロパノール、ペンタノール、ヘキサノール、オクタノール、デカノール、ベンジルアルコール等のアルコール類、ポリエチレングリコール、プロピレングリコール、エチレングリコール、ジエチレングリコール、ジプロピレングリコール、グリセリン等の多価アルコール類、イソステアリン酸、ラウリン酸等の脂肪酸類、ミリスチン酸イソプロピル、ミリスチン酸オクチルドデシル、パルミチン酸イソプロピル等の脂肪酸エステル類等が挙げられる。
防腐剤、抗酸化剤、その他の安定化剤等としては、例えば、チモール、パラオキシ安息香酸メチル(メチルパラベン)、パラオキシ安息香酸エチル(エチルパラベン)、アスコルビン酸、ブチルヒドロキシアニソール、ジブチルヒドロキシトルエン、ビタミンE、エデト酸二ナトリウム、酒石酸等が挙げられる。
As components other than the above in the cataplasm of the present invention, general components usually used in cataplasms, that is, thickeners, wetting agents (humectants), fillers (excipients), absorption promoters, antiseptics Agents, antioxidants, general stabilizers in this type of formulation, and the like.
Examples of thickeners include, for example, synthetic water-soluble polymers such as sodium polyacrylate, polyacrylic acid, polyvinyl alcohol, and polyvinylpyrrolidone, natural polymer derivatives such as carboxymethylcellulose Na, methylcellulose, and hydroxymethylcellulose, starch, gelatin And natural products.
Examples of the wetting agent (humectant) include polyhydric alcohols such as glycerin, propylene glycol, 1,3-butylene glycol, and sorbitol.
Examples of the filler (excipient) include inorganic substances such as kaolin, zinc white, titanium oxide, talc, bentonite, hydrous aluminum silicate, and magnesium metasilicate aluminate. In the case of titanium oxide, it can be used not only as a filler (excipient) but also for the purpose of dispersing powder, so even when other inorganic substances are used as the filler (excipient). Further, it is one of preferred embodiments to further contain titanium oxide as necessary.
Examples of the absorption promoter include alcohols such as ethanol, propanol, pentanol, hexanol, octanol, decanol, and benzyl alcohol, and polyhydric alcohols such as polyethylene glycol, propylene glycol, ethylene glycol, diethylene glycol, dipropylene glycol, and glycerin. And fatty acid esters such as isostearic acid and lauric acid, and fatty acid esters such as isopropyl myristate, octyldodecyl myristate, and isopropyl palmitate.
Examples of preservatives, antioxidants, and other stabilizers include thymol, methyl paraoxybenzoate (methylparaben), ethyl paraoxybenzoate (ethylparaben), ascorbic acid, butylhydroxyanisole, dibutylhydroxytoluene, vitamin E. Edetate disodium, tartaric acid and the like.

なお、本発明のフェルビナク含有パップ剤は、分散型フェルビナク含有パップ剤である点に特徴を有するものであるからして、フェルビナクを溶解する目的での溶解剤は不要である。フェルビナクが溶解してしまっては分散型フェルビナク含有パップ剤にはならないからである。   The felbinac-containing poultice of the present invention is characterized in that it is a dispersion-type felbinac-containing poultice, so that a dissolving agent for the purpose of dissolving felbinac is not necessary. This is because if felbinac is dissolved, it does not become a dispersible felbinac-containing cataplasm.

本発明の分散型フェルビナク含有パップ剤は、フェルビナク及び/又はその薬学的に許容し得る塩と、l−メントール及び親水性の高い界面活性剤と、更には必要に応じて、ポリエチレングリコール等の分散溶媒及び酸化チタン等の粉体の分散補助剤と、これに更に必要に応じて上記した如き増粘剤、湿潤剤(保湿剤)、充填剤(賦形剤)、吸収促進剤、防腐剤、抗酸化剤、安定化剤等の内の一以上を必要量含有させてなる粘着基剤を、例えば不織布やメリヤス布等の適当な支持体上に展延、塗布することにより容易に得ることが出来る。   The dispersible felbinac-containing cataplasm of the present invention comprises felbinac and / or a pharmaceutically acceptable salt thereof, l-menthol and a highly hydrophilic surfactant, and if necessary, a dispersion of polyethylene glycol or the like. A dispersion aid for powders such as a solvent and titanium oxide, and a thickener, a wetting agent (humectant), a filler (excipient), an absorption accelerator, a preservative, It can be easily obtained by spreading and applying an adhesive base containing a necessary amount of at least one of an antioxidant, a stabilizer and the like on a suitable support such as a nonwoven fabric or a knitted fabric. I can do it.

以下、実施例により本発明をより具体的に説明するが、本発明はこれら実施例により何ら限定されるものではない。
EXAMPLES Hereinafter, although an Example demonstrates this invention more concretely, this invention is not limited at all by these Examples.

実施例1及び2
精製水(温水)に親水性の高い非イオン界面活性剤を投入攪拌後、酸化チタン、合成ケイ酸アルミニウム及びフェルビナクを投入し攪拌分散させた。
次に、この分散液にゼラチン、エデト酸二ナトリウム、グリセリン、ポリビニルアルコール、ミリスチン酸イソプロピル、l−メントール、酒石酸、メタケイ酸アルミン酸マグネシウム、ポリアクリル酸部分中和物及びポリアクリル酸を加え、充分溶解し、且つ均一に分散するまで攪拌して、本発明のパップ剤用粘着基剤を調製した。各成分の添加量及び得られた粘着基剤の分散性並びに生成したエステル体の割合を表1に示す。
Examples 1 and 2
After adding highly hydrophilic nonionic surfactant to purified water (warm water) and stirring, titanium oxide, synthetic aluminum silicate and felbinac were added and stirred and dispersed.
Next, gelatin, disodium edetate, glycerin, polyvinyl alcohol, isopropyl myristate, l-menthol, tartaric acid, magnesium aluminate metasilicate, partially neutralized polyacrylic acid and polyacrylic acid were added to the dispersion. It stirred until it melt | dissolved and disperse | distributed uniformly and the adhesive base for cataplasms of this invention was prepared. Table 1 shows the amount of each component added, the dispersibility of the obtained adhesive base, and the ratio of the produced ester.

比較例1及び2
実施例1及び2において、親水性の高い非イオン界面活性剤の代りに親水性の低い非イオン界面活性剤を用いた以外は実施例1及び2と同様にして比較例1及び2のパップ剤用粘着基剤を調製した。各成分の添加量及び得られた粘着基剤の分散性並びに生成したエステル体の割合を表1に併せて示す。
Comparative Examples 1 and 2
In Examples 1 and 2, the cataplasm of Comparative Examples 1 and 2 was the same as in Examples 1 and 2 except that a non-ionic surfactant with low hydrophilicity was used instead of the non-ionic surfactant with high hydrophilicity. An adhesive base was prepared. Table 1 shows the added amount of each component, the dispersibility of the obtained adhesive base, and the ratio of the produced ester.

実施例3
ポリエチレングリコール400と親水性の高い非イオン界面活性剤にフェルビナクを分散させた。
次に、精製水(温水)、酸化チタン、合成ケイ酸アルミニウム、ゼラチン、エデト酸二ナトリウム、グリセリン、ポリビニルアルコール、ミリスチン酸イソプロピル、l−メントール、酒石酸、メタケイ酸アルミン酸マグネシウム、ポリアクリル酸部分中和物及びポリアクリル酸を加え、充分溶解し、且つ均一に分散するまで攪拌して、本発明のパップ剤用粘着基剤を調製した。各成分の添加量及び得られた粘着基剤の分散性並びに生成したフェルビナク−メントールエステル体の割合を表1に併せて示す。
Example 3
Felbinac was dispersed in polyethylene glycol 400 and a highly hydrophilic nonionic surfactant.
Next, in purified water (hot water), titanium oxide, synthetic aluminum silicate, gelatin, edetate disodium, glycerin, polyvinyl alcohol, isopropyl myristate, l-menthol, tartaric acid, magnesium metasilicate aluminate, polyacrylic acid A Japanese product and polyacrylic acid were added, and the mixture was sufficiently dissolved and stirred until uniformly dispersed to prepare an adhesive base for cataplasms of the present invention. Table 1 also shows the amount of each component added, the dispersibility of the obtained adhesive base, and the ratio of the produced fervinac-menthol ester.

比較例3
N−メチル−2−ピロリドンにフェルビナク及びl−メントールを溶解した。
次に、精製水(温水)、酸化チタン、合成ケイ酸アルミニウム、ゼラチン、エデト酸二ナトリウム、グリセリン、ポリビニルアルコール、酒石酸、メタケイ酸アルミン酸マグネシウム、ポリアクリル酸部分中和物、ポリアクリル酸及び本発明に係る界面活性剤を加え、充分攪拌して、比較例3のパップ剤用粘着基剤を調製した。各成分の添加量及び得られた粘着基剤の分散性並びに生成したフェルビナク−メントールエステル体の割合を表1に併せて示す。
Comparative Example 3
Felbinac and l-menthol were dissolved in N-methyl-2-pyrrolidone.
Next, purified water (warm water), titanium oxide, synthetic aluminum silicate, gelatin, edetate disodium, glycerin, polyvinyl alcohol, tartaric acid, magnesium metasilicate magnesium aluminate, polyacrylic acid partial neutralized product, polyacrylic acid and this The surfactant according to the invention was added and sufficiently stirred to prepare an adhesive base for a cataplasm of Comparative Example 3. Table 1 also shows the amount of each component added, the dispersibility of the obtained adhesive base, and the ratio of the produced fervinac-menthol ester.

比較例4
クロタミトンにフェルビナク及びl−メントールを溶解した。
次に、精製水(温水)、酸化チタン、合成ケイ酸アルミニウム、ゼラチン、エデト酸二ナトリウム、グリセリン、ポリビニルアルコール、酒石酸、メタケイ酸アルミン酸マグネシウム、ポリアクリル酸部分中和物、ポリアクリル酸及び本発明に係る界面活性剤を加え、充分攪拌して、比較例4のパップ剤用粘着基剤を調製した。各成分の添加量及び得られた粘着基剤の分散性並びに生成したフェルビナク−メントールエステル体の割合を表1に併せて示す。
Comparative Example 4
Felbinac and l-menthol were dissolved in crotamiton.
Next, purified water (warm water), titanium oxide, synthetic aluminum silicate, gelatin, edetate disodium, glycerin, polyvinyl alcohol, tartaric acid, magnesium metasilicate magnesium aluminate, polyacrylic acid partial neutralized product, polyacrylic acid and this The surfactant according to the invention was added and sufficiently stirred to prepare an adhesive base for cataplasm of Comparative Example 4. Table 1 also shows the amount of each component added, the dispersibility of the obtained adhesive base, and the ratio of the produced fervinac-menthol ester.

Figure 0005099956
Figure 0005099956

なお、表中の、生成したフェルビナク−メントールエステル体の割合の値を算出するための基となる、エステル体含量の測定法は以下とおりである。   In addition, the measuring method of ester body content used as the group for calculating the value of the ratio of the produced fervinac menthol ester body in a table | surface is as follows.

製剤中のフェルビナク−メントールエステル体の定量
各粘着基剤をそれぞれ不織布に展延、塗布して作製したパップ剤製剤35cmを切り取り、質量を量り、初期質量とした。これを、メタノール70mL中に入れ、30分間振盪抽出した後、抽出液にメタノールを加えて正確に100mLとした。この溶液3mLに移動相3mLを加えて試料溶液とした。
別に、フェルビナク−メントールエステル体20mgを秤量し、メタノールに溶解して100mLとした。この溶液1mLに、更にメタノールを加えて正確に100mLとした。
この溶液3mLに、移動相3mLを加えて標準溶液とした。
試料溶液及び標準溶液をHPLC用フィルターでろ過後、各溶液20μLにつき、次の条件で液体クロマトグラフ法により試験を行った。
<試験条件>
検出器:紫外吸光光度計(測定波長:254nm)
力ラム:内径約4mm、長さ15〜30cmのステンレス管に5〜10μmの液体クロ マトグラフ用オクタデシルシリル化シリカゲルを充填したもの。
力ラム温度:40℃付近の一定温度
移動相:アセトニトリル/希釈したりん酸(1→1000)=9/1
流量:1.0mL/min.
Quantitative determination of fervinac-menthol ester in the preparation 35 cm 2 of a poultice preparation prepared by spreading and applying each adhesive base on a nonwoven fabric was cut out, and the mass was measured to obtain the initial mass. This was put in 70 mL of methanol and extracted by shaking for 30 minutes, and then methanol was added to the extract to make exactly 100 mL. 3 mL of mobile phase was added to 3 mL of this solution to obtain a sample solution.
Separately, 20 mg of fervinac-menthol ester was weighed and dissolved in methanol to make 100 mL. Methanol was further added to 1 mL of this solution to make exactly 100 mL.
3 mL of mobile phase was added to 3 mL of this solution to obtain a standard solution.
The sample solution and the standard solution were filtered through a HPLC filter, and then 20 μL of each solution was tested by the liquid chromatograph method under the following conditions.
<Test conditions>
Detector: UV absorptiometer (measurement wavelength: 254 nm)
Force ram: A stainless tube having an inner diameter of about 4 mm and a length of 15 to 30 cm filled with octadecylsilylated silica gel for liquid chromatograph of 5 to 10 μm.
Power ram temperature: constant temperature around 40 ° C. Mobile phase: acetonitrile / diluted phosphoric acid (1 → 1000) = 9/1
Flow rate: 1.0 mL / min.

[考察]
実施例1、2及び3で得られた粘着基剤をそれぞれ不織布に展延、塗布して作製した本発明のパップ剤製剤は、表1中のエステル体の割合の値からも明らかなように、比較例1、2、3及び4で得られた粘着基剤をそれぞれ不織布に展延、塗布して作製したパップ剤製剤と比べて、製剤安定性が顕著に優れており、フェルビナクとl−メントールが共存する粘着基剤中に親水性の高い界面活性剤を含有させた本発明の分散型フェルビナク含有パップ剤の有効性が確認された。
なお、親水性の低い非イオン界面活性剤を用いた比較例1及び比較例2では、エステル体の割合の値は、親水性の高い非イオン界面活性剤を用いた本発明の実施例3と変りがないが、分散性が極めて悪く製剤化が困難であり、また、無理にこの状態で製剤化しても、皮膚刺激性が強く実用化に耐えない。
また、比較例3及び4は、フェルビナクの溶解剤であるN−メチル−2−ピロリドン及びクロタミトンをそれぞれ溶解に必要な量、共存させているため、本発明に係る親水性の高い界面活性剤を共存させても分散型とはならず、前者は半溶解状態、後者は溶解状態とそれぞれなっており、必然的にどちらも製剤安定性が良くなかった。
[Discussion]
The poultice preparations of the present invention prepared by spreading and applying the adhesive bases obtained in Examples 1, 2 and 3 to nonwoven fabrics, respectively, are clear from the values of the ratio of ester bodies in Table 1. Compared with the cataplasm preparation prepared by spreading and applying the adhesive bases obtained in Comparative Examples 1, 2, 3 and 4 to nonwoven fabrics, the formulation stability was remarkably superior. The effectiveness of the disperse felbinac-containing cataplasm of the present invention in which a highly hydrophilic surfactant was contained in the adhesive base in which menthol coexists was confirmed.
In Comparative Example 1 and Comparative Example 2 using a non-ionic surfactant with low hydrophilicity, the value of the ratio of the ester is the same as Example 3 of the present invention using a non-ionic surfactant with high hydrophilicity. Although there is no change, dispersibility is extremely poor and formulation is difficult, and even if it is forcibly formulated in this state, skin irritation is strong and unpractical.
In Comparative Examples 3 and 4, N-methyl-2-pyrrolidone and crotamiton, which are felbinac solubilizers, coexist in the amounts necessary for dissolution, respectively. Therefore, the highly hydrophilic surfactant according to the present invention is used. Even if it coexists, it does not become a dispersion type, the former is in a semi-dissolved state and the latter is in a dissolved state, and both of them are inevitably poor in formulation stability.

本発明は、製剤安定性が極めて良効で、且つ実用性の高い消炎鎮痛用フェルビナク含有パップ剤を提供するものであり、斯業に貢献するところ極めて大である。   The present invention provides an antiphlogistic analgesic felbinac-containing cataplasm having a very good effect on formulation stability and high practicality, and it contributes greatly to this business.

Claims (5)

フェルビナク及び/又はその薬学的に許容し得る塩(ただし、イプリフラボンを含有する場合を除く)と、l−メントール、並びにポリエチレングリコール脂肪酸エステル及びポリオキシエチレンソルビタン脂肪酸エステルからなる群から選ばれるHLB値が10以上の非イオン界面活性剤を粘着基剤中に含んでなることを特徴とする、分散型フェルビナク含有パップ剤。 HLB value selected from the group consisting of felbinac and / or a pharmaceutically acceptable salt thereof (except when it contains ipriflavone) , l-menthol, and polyethylene glycol fatty acid ester and polyoxyethylene sorbitan fatty acid ester A disperse felbinac-containing cataplasm containing 10 or more nonionic surfactants in an adhesive base. 粘着基剤中に、さらに吸収促進剤が含有されている請求項1に記載の分散型フェルビナク含有パップ剤。   The disperse felbinac-containing poultice according to claim 1, wherein an absorption accelerator is further contained in the adhesive base. 粘着基剤が、ポリビニルアルコール、ポリアクリル酸、及びゼラチンからなる群から選ばれる増粘剤を含有する請求項1又は2に記載の分散型フェルビナク含有パップ剤。   The dispersion type felbinac-containing poultice according to claim 1 or 2, wherein the adhesive base contains a thickener selected from the group consisting of polyvinyl alcohol, polyacrylic acid, and gelatin. 粘着基剤中に更にポリエチレングリコールを含有する、請求項1〜3の何れかに記載の分散型フェルビナク含有パップ剤。   The disperse felbinac-containing poultice according to any one of claims 1 to 3, further comprising polyethylene glycol in the adhesive base. 粘着基剤中に、更に酸化チタンを含有する、請求項1〜4の何れかに記載の分散型フェルビナク含有パップ剤。   The disperse felbinac-containing poultice according to any one of claims 1 to 4, further comprising titanium oxide in the adhesive base.
JP2003426144A 2003-12-24 2003-12-24 New anti-inflammatory analgesic cataplasm Expired - Lifetime JP5099956B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003426144A JP5099956B2 (en) 2003-12-24 2003-12-24 New anti-inflammatory analgesic cataplasm

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003426144A JP5099956B2 (en) 2003-12-24 2003-12-24 New anti-inflammatory analgesic cataplasm

Publications (2)

Publication Number Publication Date
JP2005179312A JP2005179312A (en) 2005-07-07
JP5099956B2 true JP5099956B2 (en) 2012-12-19

Family

ID=34785763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003426144A Expired - Lifetime JP5099956B2 (en) 2003-12-24 2003-12-24 New anti-inflammatory analgesic cataplasm

Country Status (1)

Country Link
JP (1) JP5099956B2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812268B2 (en) * 2004-08-03 2011-11-09 リンテック株式会社 Volatilization inhibitor, volatile component-containing composition and patch
FR2879931B1 (en) * 2004-12-24 2007-03-30 Rhodia Chimie Sa SILICONE MATERIAL FOR THE RELEASE OF AN ACTIVE MOLECULE
JP2013040200A (en) * 2006-03-31 2013-02-28 Daiichi Sankyo Healthcare Co Ltd Antioxidant and/or anti-inflammatory and analgesic agent
JP2007291069A (en) * 2006-03-31 2007-11-08 Daiichi Sankyo Healthcare Co Ltd Antioxidant and/or analgesic and anti-inflammatory agent
ES2642274T3 (en) * 2011-02-02 2017-11-16 Nitto Denko Corporation Patch Preparation
JPWO2020262057A1 (en) 2019-06-24 2020-12-30

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10338633A (en) * 1997-04-08 1998-12-22 Takeda Chem Ind Ltd Composition for treatment and prevention for periodontal disease
JP4214343B2 (en) * 1999-10-22 2009-01-28 ライオン株式会社 Patches and cooling sheets
JP2001122771A (en) * 1999-10-25 2001-05-08 Lion Corp Method for producing hydrous paste
JP4585074B2 (en) * 2000-03-28 2010-11-24 ライオン株式会社 Method for producing pharmaceutical composition
JP2002145763A (en) * 2000-11-10 2002-05-22 Lion Corp Cataplasm

Also Published As

Publication number Publication date
JP2005179312A (en) 2005-07-07

Similar Documents

Publication Publication Date Title
JP4549006B2 (en) Gel ointment
JP2010521442A (en) Topical formulation
JP5052558B2 (en) Gel ointment
KR20110017451A (en) Analgesic anti-inflammatory preparation for external application
WO2013081102A1 (en) Ropinirole-containing adhesive patch
JP7438566B2 (en) patch
JP4195178B2 (en) Anti-inflammatory analgesic topical
JP5099956B2 (en) New anti-inflammatory analgesic cataplasm
WO2009119601A1 (en) Water-based adhesive skin patch comprising ketoprofen lysine salt
JP3056694B2 (en) Novel therapeutic anti-inflammatory analgesic pharmaceutical composition and method for producing the same
JP3091285B2 (en) External anti-inflammatory analgesic
WO1991012821A1 (en) Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic
JPH05201879A (en) Percutaneous administration pharmaceutical
JP4066466B2 (en) Ointment containing sugar alcohols
US9254325B2 (en) Percutaneously absorbed preparation
JP7108681B2 (en) (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide A pharmaceutical composition comprising
KR101894891B1 (en) Topical gel composition containing dexibuprofen emulsion with enhaced permeability
JP3599766B2 (en) Patch preparation
JPH09208463A (en) Anti-inflammatory and analgesic composition excellent in transdermal absorbability
JP4974535B2 (en) External preparation and method for producing the same
JP2001058961A (en) Percutaneous absorbefacient and percutaneous absorption-type preparation
JP2935113B1 (en) Indomethacin transdermal absorbent
JP2000297036A (en) Anti-inflammatory and analgesic agent for external use
JP2008231081A (en) Ketoprofen-containing external preparation
JP3325039B2 (en) Skin irritation alleviating composition and transdermal external preparation containing the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101007

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101101

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101217

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120925

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151005

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5099956

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term